At a glance
ClinicalIndex Comparison RecordN/ACompleted· 317 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment Patterns And Clinical Outcomes Among Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (mBC) Receiving Palbociclib in Combination With Fulvestrant (PB+FUL) In The US Community Oncology Setting
In Brief
An observational study for Breast Cancer. Completed, enrolled 317 participants across 1 site.
Detailed Summary
By leveraging a community-based, cancer-specific electronic healthcare record for this study, we aim to understand treatment patterns and clinical outcomes among patients with HR+/HER2- mBC who received care within the context of a large community oncology network in the United States.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedJul 2020
Primary CompletionApr 2022
TodayJul 2026
First PostedJul 8, 2020
Enrollment StartOct 19, 2019
Primary CompletionApr 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.0 years ago